Human TFPI Alexa Fluor® 594-conjugated Antibody

Applications

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Background: TFPI

Human TFPI, also known as lipoprotein-associated coagulation inhibitor (LACI) and extrinsic pathway inhibitor (EPI), is a physiological inhibitor of extrinsic pathway of coagulation and has biological functions of anticoagulation and anti-inflammation (1). It is a secreted protein with a N-terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C-terminal basic region (2). The first K domain (residues 54 to 104) inhibits coagulation factor VIIa complexed to tissue factor (TF). The second K domain (residues 125 to 175) inhibits factor Xa. The third K domain (residues 217 to 267) binds to heparin (3). The C-terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces (2). The purified rhTFPI ends at residue 282 and does not contain the last 20 residues (residues 283 to 302) in the C-terminal region. It inhibits the activity of rhCoagulation Factor VII (R&D Systems, Catalog # 2338-SE) in the presence of rhTissue Factor (R&D Systems, Catalog # 2339-PA). Human TFPI shares 60%, 59% and 58% amino acid sequence identity with rat, mouse and canine TFPI, respectively.

Product Datasheets

Related Research Areas

• Alpha Granule Soluble Molecules
• Coagulation
• Endothelial Cell Coagulation Molecules
• Inflammatory Mediators
• Serine Proteases and Regulators